These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 24519187)

  • 1. Economic assessment of aseptic compounding rooms in hospital pharmacies in five European countries.
    Dekyndt B; Décaudin B; Lannoy D; Odou P
    J Oncol Pharm Pract; 2015 Apr; 21(2):102-10. PubMed ID: 24519187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choosing a Vial Processing Line for Aseptic Compounding: Part 1.
    Noorian S; Vahedi N
    Int J Pharm Compd; 2016; 20(4):283-292. PubMed ID: 28333673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for airborne contamination in turbulent- and unidirectional-airflow compounding aseptic isolators.
    Peters GF; McKeon MR; Weiss WT
    Am J Health Syst Pharm; 2007 Mar; 64(6):622-31. PubMed ID: 17353571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the implementation of vasoactive drug protocols on costs in the treatment of critically ill patients.
    Cuesta-López I; Sánchez-Cuervo M; Candela-Toha Á; Benedí-González J; Bermejo-Vicedo T
    Farm Hosp; 2018 Mar; 42(2):62-67. PubMed ID: 29501057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Economical assessment of intravenous mixture centralization].
    Martínez-Tutor MJ
    Farm Hosp; 2006; 30(6):351-8. PubMed ID: 17298192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Costs of a cytostatic drug preparation unit in a hospital in Mexico].
    Martínez Rodríguez OA; Rivas Bocanegra RE; Ascencio-Pérez IS; Zapata Sánchez LA
    Farm Hosp; 2007; 31(6):375-8. PubMed ID: 18348668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of two work practice changes on the microbial contamination rates of pharmacy-compounded sterile preparations.
    Trissel LA; Gentempo JA; Saenz LM; Woodard MY; Angeles CH
    Am J Health Syst Pharm; 2007 Apr; 64(8):837-41. PubMed ID: 17420200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiological performance of a robotic system for aseptic compounding of cytostatic drugs.
    Geersing TH; Franssen EJF; Pilesi F; Crul M
    Eur J Pharm Sci; 2019 Mar; 130():181-185. PubMed ID: 30710619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of the cytostatic drugs unit in rationalization of hospital drugs management--the case study and the analysis of drug utilization].
    Zuziak S; Topór-Madry R; Pilc A; Bochenek T
    Pol Merkur Lekarski; 2014 Jul; 37(217):43-8. PubMed ID: 25154199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. End-preparation assessments and tests for compounded sterile preparations.
    McElhiney LF
    Int J Pharm Compd; 2013; 17(4):307-11. PubMed ID: 24261146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survey of sterile product compounding practices in Canadian hospital pharmacies.
    Fitch DP; Hall KW
    Can J Hosp Pharm; 1993 Dec; 46(6):249-60. PubMed ID: 10131343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does your pharmacy have a compounding isolator?
    LaBella CJ
    Am J Health Syst Pharm; 2007 Apr; 64(8):855-8. PubMed ID: 17420203
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacists' Perceptions of the Economic Value of Compounded Pharmaceuticals: A Comparison of Compounded and Commercial Pharmaceuticals in Select Disease States.
    Lobb WB; Wilkin NE; Holmes ER
    Int J Pharm Compd; 2015; 19(6):514-20. PubMed ID: 26891565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microbiological validation of a robot for the sterile compounding of injectable non-hazardous medications in a hospital environment.
    Sabatini L; Paolucci D; Marinelli F; Pianetti A; Sbaffo M; Bufarini C; Sisti M
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e63-e68. PubMed ID: 32296508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aseptic simulation test for cytotoxic drug production in isolators.
    Savry A; Correard F; Bennis Y; Roubaud S; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Mar; 71(6):476-81. PubMed ID: 24589539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Justification of a pharmacy intravenous admixture service in an Australian hospital.
    Plumridge RJ; Maher M
    Am J Hosp Pharm; 1993 Mar; 50(3):463-6. PubMed ID: 8442462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost of functioning of a centralised pharmaceutical unit: evaluation of mean costs of chemotherapy preparations according to the level of production of the unit].
    Galy G; Bauler S; Buchi M; Pirot F; Pivot C
    Bull Cancer; 2011 Oct; 98(10):1153-63. PubMed ID: 22001702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Financial assessment of device for the preparation of intravenous mixtures in hospital pharmacy].
    Casado Collado A; Luengo Pascual L; Herdman M; Bonafont Pujol X; Clemente Bautista S; Jódar Masanés R; Napal Lecumberri V; Serrano Padilla G
    Farm Hosp; 2004; 28(4):243-50. PubMed ID: 15369434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved aseptic technique can reduce variable contamination rates of ward-prepared parenteral doses.
    Austin P; Elia M
    J Hosp Infect; 2013 Feb; 83(2):160-3. PubMed ID: 23313030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential for microbial contamination of ADD-Vantage admixtures.
    Hudson TJ; Ambroziak EM; Coley RM
    J Pharm Technol; 1992; 8(5):195-7. PubMed ID: 10121013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.